Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. - Wikidata - wikimedia - TriplyDB

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.

http://www.wikidata.org/entity/Q42209597

about

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?The evolving place of incretin-based therapies in type 2 diabetes Biocatalytic asymmetric synthesis of chiral amines from ketones applied to sitagliptin manufacture.Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes.The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study Effects of sitagliptin beyond glycemic control: focus on quality of life.Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema.Treating type 2 diabetes: incretin mimetics and enhancers.Defining the importance of daily glycemic control and implications for type 2 diabetes management.Incretin-based therapies: viewpoints on the way to consensus.DPP-4 inhibitors in clinical practice.Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment.Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Antihyperglycaemic therapies and cancer risk.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors.Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies.Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs.Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin.Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies.Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.Practical, asymmetric route to sitagliptin and derivatives: development and origin of diastereoselectivity.GLP-1-based therapy for diabetes: what you do not know can hurt you.Sitagliptin manufacture: a compelling tale of green chemistry, process intensification, and industrial asymmetric catalysis.Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes.

P2860

Q24628948-D264CF75-A496-4945-AC24-9B31A7321CBB Q26777177-FA3E562F-1012-4DC6-A574-C34DB553B03C Q28282265-2C1FB65F-E061-444F-9A8F-C3F52C0D1974 Q30848457-8C10D7F8-5EA4-4392-8EB6-13FAA542D97B Q31155491-B32406D5-E97E-44C4-9067-B3C80E282AA0 Q33428789-8F68624F-03FB-424C-B6C5-ABC6100A8CCD Q33562131-C9163EA5-B040-42F3-B8CA-3676451C7692 Q33562235-369459BD-C406-4477-9C6D-1476B90DEC83 Q33734024-A066F37E-D379-4CB1-8987-30FEBD159C4E Q33866808-988013FF-56E3-4EE1-9326-360EAEF3B82F Q34121402-AC9C7D87-7B38-4215-9E92-BB89CE2E9689 Q34135837-9A1D54E9-BC1E-4A29-A918-AA8701047D9C Q34620430-A4015A08-A6A0-4C33-8C3B-11EB35A9B845 Q34627077-9516B805-EF54-49D2-978C-0318313FA4A6 Q36428062-95D65FB2-C815-4F64-B71B-D4BB3CA5E893 Q36710078-605AA9C8-C737-4E34-8A54-E81FF9A8DBA3 Q36710708-5F3E74C3-0B7C-4E76-A32F-C14668E1141D Q37378498-C77E398F-58D2-4296-B77A-240A3EFCBA27 Q37609829-D0BE7699-AF75-453F-A50F-136AD8EF1A07 Q37612696-333115F6-400D-44F0-9060-9CBBF732967B Q37624267-3BA5C0F3-2877-4652-BE2E-14D49D549E8D Q37638984-E6A33454-F1B1-4915-8E3D-D1E00190F3BC Q37721962-2A1A7528-1F2A-443A-804E-EF0D973CD5A0 Q37857686-0E2ADE9F-2172-4E7F-B7C5-8C487DB57E55 Q37869699-530FFA1D-7DF9-4D3C-A0CD-A2801DE2FD1A Q38020492-093F6178-7F5D-4433-9DAA-D077429B0C22 Q38250719-6CD92EEF-5479-4996-962C-274CDCB5E2A6 Q38410742-14DF8812-76F1-412E-8287-8AD6F58CEE7E Q38541323-C6772922-9318-46F1-BF77-7D64CC16C229 Q38644070-4B3D2035-B5D7-405C-A0B5-80E478DB4FE7 Q39136054-144EFCB0-C00C-4B71-AEA1-8C4EBA09260E Q39206561-42CB0CA1-BD8F-4E72-A7E5-436AA13C558A Q41900908-80606B3A-15FD-49D9-B4CB-E647F5DC9664 Q41966262-547544E4-0EF0-472F-BB1A-CFBADBB8B3E4 Q42171281-4540D5BD-B928-4EF7-A88A-0A727409DC03 Q42585210-C8221114-4B6F-4629-83C4-90E7ADB1E243 Q42933615-453D1602-795E-4413-B7B6-34C4041C2C7E Q50527571-CB97FF8E-C823-4642-8F09-622C89114FF0 Q51759934-4397AF98-B7C3-4F93-8F98-E5E9E839AF07

P2860

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.

http://www.wikidata.org/entity/Q42209597

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Safety and tolerability of sit ...... 2 diabetes: a pooled analysis.

@en

Safety and tolerability of sit ...... 2 diabetes: a pooled analysis.

@nl

type

label

Safety and tolerability of sit ...... 2 diabetes: a pooled analysis.

@en

Safety and tolerability of sit ...... 2 diabetes: a pooled analysis.

@nl

prefLabel

Safety and tolerability of sit ...... 2 diabetes: a pooled analysis.

@en

Safety and tolerability of sit ...... 2 diabetes: a pooled analysis.

@nl

P1433

Q42209597-BC57CE92-93E2-46EA-A8E2-596A1D654364

P1476

Q42209597-4150508C-3E9F-48E2-9E3F-4DDEE76FBA2C

P2093

Q42209597-04E86C1B-2254-4F69-96F6-EEADA133529A

Q42209597-1047D4C7-31E3-42D3-BE55-CBD052237B9E

Q42209597-1750F355-3E51-4ADD-A331-4779831A679C

Q42209597-584958DE-8640-45B5-9BCF-DB41C5F8D514

Q42209597-B810DECB-A687-435B-855F-1E87FB0698B0

Q42209597-DB08DD31-1FFB-48D8-9196-D47AF5A1E711

Q42209597-E0D4143A-6DA3-4B5E-AD0D-4F50FD27F34B

Q42209597-EAE68C12-E5C9-40FA-B26C-2FA2E5FF6D6D

P2860

Q42209597-022A90DA-DAC3-4EC5-BED2-B80B032239A6

Q42209597-052C1A20-C295-45CB-82C1-34831BEE08DA

Q42209597-05E67106-24FC-4FAC-9C1E-523F506F9B3F

Q42209597-141D48B2-F09B-4E00-9223-7F525DE6DEDE

Q42209597-20D31D4C-9019-445A-86B1-5F339D6B2EE2

Q42209597-281CA640-EC65-43DF-93EB-941CAC6B819D

Q42209597-3C3A647E-C62F-492B-81CC-D47CE0CE6A79

Q42209597-3DACC63F-ABA2-47F7-A318-EB8ED0470D19

Q42209597-42D43134-86A6-4ED6-9341-96BAEB31CB0B

Q42209597-4A6AAB26-8372-4064-BFFB-AF97F938ED7C

P2888

Q42209597-94B92227-BBB1-46BE-9FF8-C32C9663795F

P304

Q42209597-6D244861-A28C-4445-8611-A0A5E9939262

P31

Q42209597-54BA0BC8-F17B-422A-B55E-9F1CD03C3826

P356

Q42209597-3552EF14-48B9-48EF-834A-60788BEB2D79

P478

Q42209597-A62A730C-E4FA-405D-8293-23168BD6BBDA

P577

Q42209597-27912CB1-7DF0-49DA-81EE-AD52B1C9883F

P5875

Q42209597-EE1A7C72-0F6E-4747-BEFB-BBA4F2A66A49

P698

Q42209597-EDDFAC46-7708-4D7C-A7EA-B4906B562A12

P921

Q42209597-ADA5CCC5-BA75-43DD-B9C0-6C0A161CF755

P932

Q42209597-ECCBC8D2-9DD5-4264-9A71-9D9D17A3AAC7

P356

P1433

BMC Endocrine Disorders

P1476

Safety and tolerability of sit ...... 2 diabetes: a pooled analysis.

@en

P2093

Arlene S Swern

http://www.w3.org/2001/XMLSchema#string

Bret Musser

http://www.w3.org/2001/XMLSchema#string

Debora Williams-Herman

http://www.w3.org/2001/XMLSchema#string

Elizabeth Round

http://www.w3.org/2001/XMLSchema#string

John M Amatruda

http://www.w3.org/2001/XMLSchema#string

Keith D Kaufman

http://www.w3.org/2001/XMLSchema#string

Michael J Davies

http://www.w3.org/2001/XMLSchema#string

Peter P Stein

http://www.w3.org/2001/XMLSchema#string

P2860

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.

CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes.

Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

P2888

P304

14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1472-6823-8-14

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23422236

http://www.w3.org/2001/XMLSchema#string

P698

18954434

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2605739

http://www.w3.org/2001/XMLSchema#string